PERINATOLOGIYA I PEDIATRIYA.2013.3(55):43–47;doi10.15574/PP.2013.55.43

Atopic dermatitis in children: optimization antipruritic therapy

Umanets T. R., Lapshin V. F., Tzhertzh L. M., Matveeva S. U.

State Institution «Institute of Pediatrics, Obstetrics and Gynecology of National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine

The aim of the study was to investigate the efficacy and tolerability to the cream «SODERMIX» in the complex treatment of children with atopic dermatitis.

Patients end methods. The study involved 67 children aged 2–8 years with mild and moderate AD. In order to optimize the antipruritic therapy in children from basic group into the combined treatment was included cream «SODERMIX.» To study the clinical efficacy of treatment used the dynamics of point scoring symptoms on a scale SCORAD, the general index of investigator assessments (IGA), the calculation of the integral indicator of pathology.

Outcomes. Research evidence that inclusion in the complex treatment of children with AD cream «SODERMIX», helped to improve efficacy of the pathogenetic treatment to control the itching and improving the repair of the skin.

Key words: atopic dermatitis, children, itch, superoxide dismutase.

REFERENCES

1. Беш ЛВ. 2009. Атопічний дерматит у дітей: прості відповіді на складні запитання. Здоров'я України. Спецвипуск Педіатрія. ХІІ: 22—23.

2. Зайков СВ. 2010. Атопічний дерматит у дітей. Дитячий лікар. 2: 51—58.

3. Калюжна ЛД, Пацеля МВ. 2010. Загальні принципи зовнішньої терапії при атопічному дерматиті. Клінічна імунологія. Алергологія та Інфектологія. 8(37).

4. Diehl C, Lipozencic J, Ledic-Drvar D. 2009. Antipruritic Effect of Natural Superoxide Dismutase — Sensory Evaluation. Acta Dermatovenerol Croat. 17(3): 217—225. PMid:19818223

5. Kunz B, Oranje AP, Labreze L et al. 1997. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 195: 10—19.

6. Akdis CA, Akdis M, Bieber T et al. 2006. Diagnosis and treatment of atopic dermatitis in children andadults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy. 61: 969—987. http://dx.doi.org/10.1111/j.1398-9995.2006.01153.x ; PMid:16867052

7. Eric B, Umasundari Sivaprasad. 2011. Th2 Cytokines and Atopic Dermatitis. J Clin Cell Immunol. 2(3): 110— 123.

8. Eyerich K, Novak N. 2013. Immunology of atopic eczema: overcoming the Th1/Th2 Paradigm. Allergy. http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1398-9995/earlyview.

9. Novak N, Simon D. 2011. Atopic dermatitis — from new pathophysiologic insights to individualized therapy. Allergy. 66: 830—839. http://dx.doi.org/10.1111/j.1398-9995.2011.02571.x ; PMid:21366605

10. Novak N. 2009. New insights into the mechanism and management of allergic diseases: atopic dermatitis. Allergy. 64: 265—275. http://dx.doi.org/10.1111/j.1398-9995.2008.01922.x ; PMid:19178406

11. Tey HL, Yosipovitch G. 2011. Targeted treatment of pruritus — a look into the future. Br J Dermatol. 165(1): 5—17. http://dx.doi.org/10.1111/j.1365-2133.2011.10217.x ; PMid:21219293 ; PMCid:PMC3125418

12. Diehl C, Lipozencic J, Ledic-Drvar D. 2009. The Basis of Topical Superoxide Dismutase Antipruritis Activity. Acta Dermatovenerol Croat. 17(1): 25—39. PMid:19386213

13. Wollenberg A, Bieber T. 2009. Proactive therapy of atopic dermatitis — an emerging concept. Allergy. 64: 276—278. http://dx.doi.org/10.1111/j.1398-9995.2008.01803.x ; PMid:19076538